Relevant bibliographies by topics / Lipogranulomatose de Farber / Journal articles

Journal articles on the topic 'Lipogranulomatose de Farber'

To see the other types of publications on this topic, follow the link: Lipogranulomatose de Farber.
Author: Grafiati
Published: 15 February 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 22 journal articles for your research on the topic 'Lipogranulomatose de Farber.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Sch�fer, A., K. Harzer, E. Kattner, H. J. Sch�fer, G. Stoltenburg, and H. Lietz. "Disseminierte Lipogranulomatose (M. Farber) mit Hydrops fetalis." Der Pathologe 17, no. 2 (March 1, 1996): 145–49. http://dx.doi.org/10.1007/s002920050148.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kim, Y. J., S. J. Park, C. K. Park, S. H. Kim, and C. W. Lee. "A case of Farber lipogranulomatosis." Journal of Korean Medical Science 13, no. 1 (1998): 95. http://dx.doi.org/10.3346/jkms.1998.13.1.95.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Alamri, Abdullah S., Daniah A. Alshowaeir, Ali A. AlFaiz, Fatimah H. Al Mousawi, Adel A. Mahmoud, and Aqeela H. Alhashim. "Optic Nerve Involvement in Farber Lipogranulomatosis." Journal of Neuro-Ophthalmology 39, no. 3 (September 2019): 391–93. http://dx.doi.org/10.1097/wno.0000000000000795.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Amirhakimi, G. H., Parviz Haghighi, M. A. Ghalambor, and S. Honari. "Familial Lipogranulomatosis (Farber's disease)." Clinical Genetics 9, no. 6 (April 23, 2008): 625–30. http://dx.doi.org/10.1111/j.1399-0004.1976.tb01624.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hodson, A., and Rosalind Coleman. "Absence seizures in Farber's lipogranulomatosis." Electroencephalography and Clinical Neurophysiology 61, no. 3 (September 1985): S186. http://dx.doi.org/10.1016/0013-4694(85)90713-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Eviatar, Lydia, Susan L. Sklower, Krystyna Wisniewski, Robert S. Feldman, and Aurora Gochoco. "Farber lipogranulomatosis: An unusual presentation in a black child." Pediatric Neurology 2, no. 6 (November 1986): 371–74. http://dx.doi.org/10.1016/0887-8994(86)90082-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Burck, U., H. W. Moser, H. H. Goebel, R. Gr�ttner, and K. R. Held. "A case of lipogranulomatosis Farber: some clinical and ultrastructural aspects." European Journal of Pediatrics 143, no. 3 (January 1985): 203–8. http://dx.doi.org/10.1007/bf00442139.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kostik, Mikhail M., Irina A. Chikova, Vladislav V. Avramenko, Laly I. Vasyakina, Emmanuelle Le Trionnaire, Vyacheslav G. Chasnyk, and Thierry Levade. "Farber lipogranulomatosis with predominant joint involvement mimicking juvenile idiopathic arthritis." Journal of Inherited Metabolic Disease 36, no. 6 (February 6, 2013): 1079–80. http://dx.doi.org/10.1007/s10545-012-9573-z.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Asada, Akira, Shigeki Tatekawa, Takekazu Terai, Masanori Hayashi, Masato Hatano, Kazutoshi Ikeshita, and Mitsugu Fujimori. "The Anesthetic Implications of a Patient with Farber's Lipogranulomatosis." Anesthesiology 80, no. 1 (January 1, 1994): 206–8. http://dx.doi.org/10.1097/00000542-199401000-00028.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

CHANOKI, M., M. ISHII, K. FUKAI, H. KOBAYASHI, T. HAMADA, K. MURAKAMI, and A. TANAKA. "Farber's lipogranulomatosis in siblings: light and electron microscopic studies." British Journal of Dermatology 121, no. 6 (December 1989): 779–85. http://dx.doi.org/10.1111/j.1365-2133.1989.tb08222.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Frohbergh, Michael, Xingxuan He, and Edward H. Schuchman. "The molecular medicine of acid ceramidase." Biological Chemistry 396, no. 6-7 (June 1, 2015): 759–65. http://dx.doi.org/10.1515/hsz-2014-0290.

Full text
Abstract:
Abstract Acid ceramidase (N-acylsphingosine deacylase, EC 3.5.1.23; AC) is the lipid hydrolase responsible for the degradation of ceramide into sphingosine and free fatty acids within lysosomes. The enzymatic activity was first identified over four decades ago and is deficient in two rare inherited disorders, Farber lipogranulomatosis (Farber disease) and spinal muscular atrophy with myoclonic epilepsy (SMA-PME). Importantly, AC not only hydrolyzes ceramide into sphingosine within acidic compartments, but also can synthesize ceramide from sphingosine at neutral pH, suggesting that the enzyme may have diverse functions depending on its subcellular location and the local pH. Within cells, AC exists in a complex with other lipid hydrolases and requires a polypeptide cofactor (saposin D) for full hydrolytic activity. Recent studies also have shown that AC is overexpressed in several human cancers, and that inhibition of this enzyme may be a useful cancer drug target. Aberrant AC activity has also been described in several other common diseases. The cDNA and gene (ASAH1) encoding AC have been isolated, several mouse models of AC deficiency have been constructed, and the recombinant enzyme is currently being manufactured for the treatment of Farber disease and SMA-PME. Current information concerning the biology of this enzyme and its role in human disease is reviewed within.
APA, Harvard, Vancouver, ISO, and other styles
12

Hadipour, F., Z. Hadipour, A. Tavassoli, and Y. Shafaghati. "Farber Disease or Lipogranulomatosis; 4 Case Reports of New Mutations in the Ceramidase Gene." Sarem Journal of Reproductive Medicine 2, no. 3 (July 1, 2017): 133–36. http://dx.doi.org/10.29252/sjrm.2.3.133.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Bashyam, M. D., A. K. Chaudhary, M. Kiran, V. Reddy, H. A. Nagarajaram, A. Dalal, L. Bashyam, et al. "Molecular analyses of novelASAH1mutations causing Farber lipogranulomatosis: analyses of exonic splicing enhancer inactivating mutation." Clinical Genetics 86, no. 6 (December 20, 2013): 530–38. http://dx.doi.org/10.1111/cge.12316.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Schuchman, Edward H., Michael Frohbergh, Johana M. Guevara, Xingxuan He, Victor A. DeAngelis, and Calogera M. Simonaro. "Cartilage and bone disease in a mouse model of Farber lipogranulomatosis and response to treatment." Molecular Genetics and Metabolism 117, no. 2 (February 2016): S103. http://dx.doi.org/10.1016/j.ymgme.2015.12.431.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Devi, Akela Radha Rama, Munimanda Gopikrishna, Raman Ratheesh, Gorinabele Savithri, Gowrishankar Swarnalata, and Murali Bashyam. "Farber lipogranulomatosis: clinical and molecular genetic analysis reveals a novel mutation in an Indian family." Journal of Human Genetics 51, no. 9 (September 2006): 811–14. http://dx.doi.org/10.1007/s10038-006-0019-z.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Choudhary, Nitin, Sonia Wadhawan, Rahil Singh, and Poonam Bhadoria. "Anaesthetic management of a child with Farber's lipogranulomatosis posted for exploratory laparotomy." Indian Journal of Anaesthesia 63, no. 11 (2019): 953. http://dx.doi.org/10.4103/ija.ija_418_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Nowaczyk, M. J. M., A. Feigenbaum, M. M. Silver, J. Callahan, A. Levin, and V. Jay. "Bone marrow involvement and obstructive jaundice in Farber lipogranulomatosis: clinical and autopsy report of a new case." Journal of Inherited Metabolic Disease 19, no. 5 (September 1996): 655–60. http://dx.doi.org/10.1007/bf01799842.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Koga, Mayumi, Tokuhiro Ishihara, Fumiya Uchino, and Takehisa Fujiwaki. "An Autopsy Case of Farber's Lipogranulomatosis in a Japanese Boy with Gastrointestinal Involvement." Pathology International 42, no. 1 (January 1992): 42–48. http://dx.doi.org/10.1111/j.1440-1827.1992.tb01109.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Cvitanovic-Sojat, L., R. Gjergja Juraski, F. Sabourdy, A. H. Fensom, K. Fumic, E. Paschke, and T. Levade. "Farber lipogranulomatosis type 1 – Late presentation and early death in a Croatian boy with a novel homozygous ASAH1 mutation." European Journal of Paediatric Neurology 15, no. 2 (March 2011): 171–73. http://dx.doi.org/10.1016/j.ejpn.2010.06.002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

He, Xingxuan, and Edward H. Schuchman. "Identification of a Novel Acid Sphingomyelinase Activity Associated with Recombinant Human Acid Ceramidase." Biomolecules 13, no. 11 (November 6, 2023): 1623. http://dx.doi.org/10.3390/biom13111623.

Full text
Abstract:
Acid ceramidase (AC) is a lysosomal enzyme required to hydrolyze ceramide to sphingosine by the removal of the fatty acid moiety. An inherited deficiency in this activity results in two disorders, Farber Lipogranulomatosis and spinal muscular atrophy with myoclonic epilepsy, leading to the accumulation of ceramides and other sphingolipids in various cells and tissues. In addition to ceramide hydrolysis, several other activities have been attributed to AC, including a reverse reaction that synthesizes ceramide from free fatty acids and sphingosine, and a deacylase activity that removes fatty acids from complex lipids such as sphingomyelin and glycosphingolipids. A close association of AC with another important enzyme of sphingolipid metabolism, acid sphingomyelinase (ASM), has also been observed. Herein, we used a highly purified recombinant human AC (rhAC) and novel UPLC-based assay methods to investigate the recently described deacylase activity of rhAC against three sphingolipid substrates, sphingomyelin, galactosyl- and glucosylceramide. No deacylase activities were detected using this method, although we did unexpectedly identify a significant ASM activity using natural (C-18) and artificial (Bodipy-C12) sphingomyelin substrates as well as the ASM-specific fluorogenic substrate, hexadecanoylamino-4-methylumbelliferyl phosphorylcholine (HMU-PC). We showed that this ASM activity was not due to contaminating, hamster-derived ASM in the rhAC preparation, and that the treatment of ASM-knockout mice with rhAC significantly reduced sphingomyelin storage in the liver. However, unlike the treatment with rhASM, this did not lead to elevated ceramide or sphingosine levels.
APA, Harvard, Vancouver, ISO, and other styles
21

Baz Bartels, M., S. Vlaho, V. Boda, J. Althaus, S. Geb, T. Klingebiel, L. Porto, and M. Kieslich. "Osseous Lesion at a 10 year old patient with Lipogranulomatosis (Farber Disease)." Neuropediatrics 39, no. 01 (February 2008). http://dx.doi.org/10.1055/s-2008-1079542.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Zhang, Hanmeng, Murtaza S. Nagree, Haoyuan Liu, Xiaoqing Pan, Jeffrey A. Medin, and Daniel M. Lipinski. "rAAV-mediated over-expression of acid ceramidase prevents retinopathy in a mouse model of Farber lipogranulomatosis." Gene Therapy, July 28, 2022. http://dx.doi.org/10.1038/s41434-022-00359-w.

Full text
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography